Study study type PathologyT1T0Patientssample sizesROB Results

mHCC - (neo)adjuvant (NA) metastatic/advanced hepatocellular cancer (mHCC) mHCC - (neo)adjuvant (NA)

versus Standard of Care (SoC)
atezolizumab plus bevacizumab
IMbrave050, 2023
  NCT04102098
RCTmHCC - (neo)adjuvant (NA)atezolizumab plus bevacizumabactive surveillanceadult patients with high-risk surgically resected or ablated hepatocellular carcinoma334 / 334NA
conclusif
  • demonstrated 28 % decrease in RFS/DFS (PE)

mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)

versus sorafenib
atezolizumab plus bevacizumab
IMbrave-150, 2020
  NCT03434379
RCTmHCC - 1st line (L1)atezolizumab-bevacizumabsorafenibpatients with unresectable hepatocellular carcinoma who had not previously received systemic treatment336 / 165some concern
conclusif
  • demonstrated 42 % decrease in deaths (OS) (PE)
  • demonstrated 41 % decrease in progression or deaths (PFS) (PE)
  • demonstrated 1.8-fold increase in objective responses (ORR) (PE)